Cenforce-200 is a medication that is primarily used for the treatment of erectile dysfunction in men. The active ingredient in this medication is Sildenafil, which is a PDE5 inhibitor. Cenforce-200 is classified as a PDE5 inhibitor because it works by inhibiting the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP), which is responsible for causing the smooth muscles in the penis to relax. This allows more blood to flow into the penis, which helps to produce and maintain an erection.
The active half-life of Cenforce-200 is approximately 8 hours, which means that it can stay in the body for up to 8 hours after ingestion. The recommended dosage of Cenforce-200 for men is between 100-200 mg per day, although the exact dosing will depend on individual factors such as age, health, and the severity of the erectile dysfunction.
One of the benefits of using Cenforce-200 for the treatment of erectile dysfunction is that it does not cause acne or water retention. However, it is possible that it may cause headache, nausea, dizziness, or other common side effects associated with PDE5 inhibitors. Additionally, Cenforce-200 may increase the risk of heart attack, stroke, or other cardiovascular events, particularly in men who have pre-existing medical conditions.
Overall, Cenforce-200 is a relatively safe and effective medication for the treatment of erectile dysfunction. It is manufactured by Centurion Laboratories and is available in a pack of 10 pills, each of which contains 200 mg of Sildenafil. Patients who are considering using Cenforce-200 to treat their erectile dysfunction should talk to their doctor to determine whether this medication is right for them and to discuss potential side effects and interactions with other medications.
Chemical name: 1-((3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
Formula: C28H38N6O11S
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
Reviews
There are no reviews yet.